This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
ONCOassist® | The go-to oncology app
oncoassist.bsky.social
did:plc:37ke4hieqksucnwp4a3htxwj
🚨BREAKING: The Phase III PACIFIC-2 study explores concurrent durvalumab with platinum-based chemoradiotherapy in unresectable Stage III NSCLC
🔹 Immunotherapy targeting PD-L1 has improved outcomes when given after cCRT.
🔗 bit.ly/ONCOnews14O-1
#ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC
2025-10-14T11:00:07.923Z